Philip W. Ruff, PhD, BSc, CChem MRSC, CSci
Director, Global Market Access, Shire Pharmaceuticals
Philip W. Ruff is Director of Global Market Access for Shire’s Rare Disease pipeline products. He is also part of the Shire Comparative Effectiveness Research advisory team. Previously, he was commercial head of Medeval, the UK’s largest Phase I contract research organization. In 2004, he joined Abbott Laboratories in a policy role, leading their evidence-based medicine policy initiative and representing Abbott on several PhRMA committees. In 2007, he joined Amgen, where he was responsible for the development and implementation of an internal health technology assessment/comparative effectiveness research (CER) resource center and was part of a team that implemented CER readiness for its products. In 2011, he joined Millennium Pharmaceuticals, focusing on the development of its emerging oncology pipeline. He received a BSc and PhD in Chemistry from the University of Leicester, is a Chartered Chemist and Member of the Royal Society of Chemistry, and holds the EU Chartered Scientist designation.
Ruff served as a member of the Advisory Panel on Rare Disease from April 2014 - April 2016.
Conflicts of Interest
As of April 30, 2014:
- Shire Pharmaceuticals, Employee and Stock
- Sarepta Therapeutic, Employee and Stock (Spouse)
- Sarepta Therapeutic, Stock (Sons)
- Advisory Panel Member